Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial

IMPORTANCE: Approximately 25% of patients with early-stage breast cancer who receive (neo)adjuvant chemotherapy experience a recurrence within 5 years. Improvements in therapy are greatly needed. OBJECTIVE: To determine if pembrolizumab plus neoadjuvant chemotherapy (NACT) in early-stage breast canc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Nanda, Rita, Liu, Minetta C., Yau, Christina, Shatsky, Rebecca, Pusztai, Lajos, Wallace, Anne, Chien, A. Jo, Forero-Torres, Andres, Ellis, Erin, Han, Heather, Clark, Amy, Albain, Kathy, Boughey, Judy C., Jaskowiak, Nora T., Elias, Anthony, Isaacs, Claudine, Kemmer, Kathleen, Helsten, Teresa, Majure, Melanie, Stringer-Reasor, Erica, Parker, Catherine, Lee, Marie C., Haddad, Tufia, Cohen, Ronald N., Asare, Smita, Wilson, Amy, Hirst, Gillian L., Singhrao, Ruby, Steeg, Katherine, Asare, Adam, Matthews, Jeffrey B., Berry, Scott, Sanil, Ashish, Schwab, Richard, Symmans, W. Fraser, van ‘t Veer, Laura, Yee, Douglas, DeMichele, Angela, Hylton, Nola M., Melisko, Michelle, Perlmutter, Jane, Rugo, Hope S., Berry, Donald A., Esserman, Laura J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2020
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7058271/
https://ncbi.nlm.nih.gov/pubmed/32053137
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.6650
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados